- Trials with a EudraCT protocol (815)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
815 result(s) found for: prostate cancer OR breast cancer.
Displaying page 1 of 41.
| EudraCT Number: 2011-005168-14 | Sponsor Protocol Number: UMCN-AKF11.01 | Start Date*: 2012-05-14 | ||||||||||||||||
| Sponsor Name:Radboud University Nijmegen Medical Centre | ||||||||||||||||||
| Full Title: Lean Body Mass as a determinant of docetaxel pharmacokinetics and toxicity (LEANDOC) | ||||||||||||||||||
| Medical condition: Exposure and toxicity of docetaxel treatment with patients with breast or metastatic castration-resistant prostate carcinoma. | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: NL (Prematurely Ended) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2020-002667-53 | Sponsor Protocol Number: 213409 | Start Date*: 2021-08-23 | |||||||||||||||||||||
| Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||||||||||||
| Full Title: An Open-Label, Multicenter, Long-term Treatment Extension Study in Subjects Who Have Completed a Prior GlaxoSmithKline/TESARO-Sponsored Niraparib Study and are Judged by the Investigator to Benefit... | |||||||||||||||||||||||
| Medical condition: advanced ovarian, breast, or prostate cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: AT (Trial now transitioned) FR (Trial now transitioned) DK (Completed) ES (Ongoing) IT (Trial now transitioned) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2005-002132-94 | Sponsor Protocol Number: CZOL446EDE28 | Start Date*: 2008-08-18 | |||||||||||
| Sponsor Name:Novartis Pharma GmbH | |||||||||||||
| Full Title: „Effect of intravenous Zoledronic Acid on Bone Metabolism given over 4 month in patients with prostate cancer or breast cancer and bone metastasis. A prospective, single-arm multicenter study” (Z... | |||||||||||||
| Medical condition: Patients with prostate or breast cancer with bone metastasis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2010-022278-15 | Sponsor Protocol Number: D0810C00042 | Start Date*: 2010-10-25 | ||||||||||||||||||||||||||
| Sponsor Name:AstraZeneca AB | ||||||||||||||||||||||||||||
| Full Title: A Phase II, Open Label, Non Randomised, Non Comparative, Multicentre Study to Assess the Efficacy And Safety of Olaparib Given Orally Twice Daily in Patients With Advanced Cancers Who Have A Confir... | ||||||||||||||||||||||||||||
| Medical condition: Patients With Advanced Cancers Who Have A Confirmed Genetic BRCA1 And/Or BRCA2 Mutation | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: DE (Completed) SE (Completed) ES (Ongoing) | ||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||
| EudraCT Number: 2014-002407-25 | Sponsor Protocol Number: 16996 | Start Date*: 2014-11-25 | |||||||||||||||||||||
| Sponsor Name:Bayer AG | |||||||||||||||||||||||
| Full Title: A Phase 4 long-term follow-up study to define the safety profile of radium-223 dichloride | |||||||||||||||||||||||
| Medical condition: Castrate Resistant Prostate Cancer/Hormone-Refractory Prostate Cancer, breast cancer or multiple myeloma patients with bone metastasis | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: DE (Completed) SE (Completed) ES (Completed) FR (Completed) BE (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) FI (Completed) PL (Completed) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2019-004730-42 | Sponsor Protocol Number: IQVIA-ODYS-001-LZA45541 | Start Date*: 2022-10-24 | |||||||||||||||||||||||||||||||
| Sponsor Name:IQVIA RDS FRANCE SAS | |||||||||||||||||||||||||||||||||
| Full Title: Prospective evaluation of potential effects of repeated gadolinium-based contrast agent (GBCA) administrations of the same GBCA on motor and cognitive functions in neurologically normal adults in c... | |||||||||||||||||||||||||||||||||
| Medical condition: Long term potential effect of repeated exposure to either a linear or a macrocyclic gadolinium-based contrast agent (GBCA) on change from baseline to Year 5 in motor and cognitive function among ne... | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||||||||||||
| Trial protocol: NL (Completed) IT (Trial now transitioned) FR (Trial now transitioned) | |||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||
| EudraCT Number: 2019-003777-26 | Sponsor Protocol Number: D0817C00098 | Start Date*: 2020-05-27 | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:AstraZeneca AB | ||||||||||||||||||||||||||||||||||||||
| Full Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study with Olaparib and Are Judged by the Investigator to Clinically Benefit From Continued Treatment | ||||||||||||||||||||||||||||||||||||||
| Medical condition: BRCA Mutated Ovarian Cancer Patients, Epithelian ovarian cancer, Metastatic Breast Cancer, Platinum Sensitive Relapsed Ovarian Cancer, Patients with gBRCA mutated metastatic pancreatic cancer, | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: BG (Trial now transitioned) HU (Trial now transitioned) PL (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) DE (Trial now transitioned) IT (Trial now transitioned) DK (Completed) BE (Trial now transitioned) SE (Trial now transitioned) FI (Completed) PT (Trial now transitioned) SI (Trial now transitioned) FR (Trial now transitioned) | ||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2013-004398-28 | Sponsor Protocol Number: AA01 | Start Date*: 2016-06-17 | ||||||||||||||||||||||||||
| Sponsor Name:Medical Research Council Clinical Trials Unit at UCL [...] | ||||||||||||||||||||||||||||
| Full Title: A phase III double-blind placebo-controlled randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours. | ||||||||||||||||||||||||||||
| Medical condition: Cancer (breast, colorectal, gastro-oesophageal and prostate) | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) IE (Trial now transitioned) | ||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||
| EudraCT Number: 2013-001249-15 | Sponsor Protocol Number: 314-12-401 | Start Date*: 2013-11-07 | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:Otsuka Novel Products GmbH | ||||||||||||||||||||||||||||||||||||||
| Full Title: A Two-Part Phase 1/2a, Open-Label, Dose-Escalation Study to Evaluate the Tolerability and Preliminary Antitumour Activity of OPB-111001 in Patients with Advanced Cancers that are Poorly Responsive ... | ||||||||||||||||||||||||||||||||||||||
| Medical condition: • Advanced prostate cancer • Advanced epithelial ovarian cancer, advanced squamous cell carcinoma of the cervix, advanced breast cancer, endometrial cancer, and salivary gland cancer that are p... | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: GB (Prematurely Ended) | ||||||||||||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2021-006227-17 | Sponsor Protocol Number: D8410C00001 | Start Date*: 2022-09-14 | |||||||||||||||||||||||||||||||
| Sponsor Name:AstraZeneca AB | |||||||||||||||||||||||||||||||||
| Full Title: A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD9574 as Monotherapy an... | |||||||||||||||||||||||||||||||||
| Medical condition: Module 1: advanced/relapsed ovarian, breast, pancreatic or prostate cancer where patients loss of function or predicted loss of function mutation in BRCA1, BRCA2, PALB2, RAD51C, or RAD51D Mdoule 2:... | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
| Trial protocol: SE (Trial now transitioned) ES (Ongoing) | |||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||
| EudraCT Number: 2020-005087-66 | Sponsor Protocol Number: 75669 | Start Date*: 2021-01-14 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Deventer Hospital | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: The Effect of Enzalutamide on Oxycodone Metabolism in Men with Prostate Cancer | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Prostate Cancer | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: NL (Ongoing) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2017-003432-37 | Sponsor Protocol Number: A005D-E01-201 | Start Date*: 2018-02-06 | |||||||||||||||||||||||||||||||
| Sponsor Name:Advanced Accelerator Applications International SA | |||||||||||||||||||||||||||||||||
| Full Title: Phase II study of preliminary diagnostic performance of [68Ga]-NeoBOMB1 in adult patients with malignancies known to overexpress Gastrin Releasing Peptide Receptor | |||||||||||||||||||||||||||||||||
| Medical condition: Malignancies known to overexpress Gastrin-Releasing Peptide Receptors | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
| Trial protocol: AT (Prematurely Ended) | |||||||||||||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||||||||||||
| EudraCT Number: 2004-005088-17 | Sponsor Protocol Number: CZOL446EHU03 | Start Date*: 2005-05-26 |
| Sponsor Name:Novartis Hungária Ltd. | ||
| Full Title: A multicenter, Open-label Study to Determine the Effect of I.V. Zometa on Pain and Quality of Life in Patients with Bone Metastases with or without Skeletal Related Events (SREs) Resulting from Bre... | ||
| Medical condition: Patients will have bone metastases with or without skeletal related events (SREs) from breast cancer and prostate cancer. | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: HU (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2004-003495-11 | Sponsor Protocol Number: GOUP 01/2004 | Start Date*: 2005-03-16 | |||||||||||
| Sponsor Name:AZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO | |||||||||||||
| Full Title: PHASE III STUDY OF CHEMOHORMONAL THERAPY WITH TO DIFFERENT MODALITIES CONCOMITANT OR ALTERNATE VERSUS HORMONAL THERAPY ALONE IN ADVANCED PROSTATE CANCER PATIENTS. | |||||||||||||
| Medical condition: ADVANCED PROSTATE CANCER | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male | ||||||||||||
| Trial protocol: IT (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2004-000495-14 | Sponsor Protocol Number: D7913L00031 | Start Date*: 2005-03-14 | |||||||||||
| Sponsor Name:ASTRAZENECA | |||||||||||||
| Full Title: A PHASE II, MULTICENTRE, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF ZD1839 (IRESSA?) IN COMBINATION WITH CASODEX? IN PATIENTS WITH OPERABLE PROSTATE CANCER | |||||||||||||
| Medical condition: OPERABLE PROSTATE CANCER | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male | ||||||||||||
| Trial protocol: IT (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2009-012809-19 | Sponsor Protocol Number: CLIN902 PCM203 | Start Date*: 2009-07-15 | |||||||||||
| Sponsor Name:STEBA BIOTECH SA | |||||||||||||
| Full Title: VASCULAR-TARGETED PHOTODYNAMIC THERAPY USING WST11 IN PATIENTS WITH LOCALISED PROSTATE CANCER | |||||||||||||
| Medical condition: Localized prostate cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male | ||||||||||||
| Trial protocol: FR (Ongoing) NL (Completed) GB (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2017-001992-22 | Sponsor Protocol Number: ADVANCE | Start Date*: 2018-06-12 | ||||||||||||||||||||||||||
| Sponsor Name:University of Oxford | ||||||||||||||||||||||||||||
| Full Title: Phase II open label randomised safety and efficacy study of the viral vectored ChAd-MVA 5T4 vaccine in combination with PD-1 checkpoint blockade in low- or intermediate-risk localized or locally ad... | ||||||||||||||||||||||||||||
| Medical condition: Low- and intermediate-risk prostate cancer and advanced metastatic prostate cancer | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male | |||||||||||||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||
| EudraCT Number: 2008-000876-26 | Sponsor Protocol Number: CLIN801 PCM201 | Start Date*: 2008-05-02 | |||||||||||
| Sponsor Name:STEBA BIOTECH NV | |||||||||||||
| Full Title: "VASCULAR-TARGETED PHOTODYNAMIC THERAPY USING WST11 IN PATIENTS WITH LOCALISED PROSTATE CANCE" | |||||||||||||
| Medical condition: The Treatment of prostate cancer. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male | ||||||||||||
| Trial protocol: FR (Ongoing) GB (Completed) NL (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2012-001864-30 | Sponsor Protocol Number: MIP-1404-201 | Start Date*: 2012-09-25 | |||||||||||
| Sponsor Name:Molecular Insight Pharmaceuticals, Inc | |||||||||||||
| Full Title: A Phase 2 Assessment of the Diagnostic Accuracy of 99mTc-MIP-1404 Imaging in Men with High-Risk Prostate Cancer Scheduled for Radical Prostatectomy (RP) and Extended Pelvic Lymph Node Dissection (E... | |||||||||||||
| Medical condition: Prostate Cancer within prostate gland and metastatic prostate cancer in regional lymph nodes | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male | ||||||||||||
| Trial protocol: BE (Completed) HU (Completed) CZ (Completed) NL (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2004-000193-31 | Sponsor Protocol Number: PR08 | Start Date*: 2004-10-04 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name: University College London | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Prostate Cancer | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
